<DOC>
	<DOC>NCT00999882</DOC>
	<brief_summary>The main purpose of the study is to establish a safe dose of AZD8055 in patients with mild or moderate liver disease by providing information on any potential side effects this drug may cause and collecting data about how hepatocellular carcinoma responds to the drug.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Advanced stage Hepatocellular Carcinoma (HCC) confirmed by cytology or histology Advanced stage Hepatocellular Carcinoma (HCC) or metastatic Hepatocellular Carcinoma (HCC) which is inoperable and incurable with standard available treatments Relatively good overall health other than cancer (WHO performance status (02) Patients with severe heart conditions, or those who have had heart surgery such as coronary artery bypass graft within the last 6 months, or patients with uncontrolled high blood pressure despite medical management. Patients must not have received any other anti cancer therapy including TACE within 21 days of entering the trial Patients must not have received a liver transplant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>mTor Kinase Inhibitor</keyword>
	<keyword>Phase I/II</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Hepatocellular carcinoma (HCC)</keyword>
	<keyword>Asia</keyword>
	<keyword>HCC</keyword>
	<keyword>Safety and pharmacokinetics</keyword>
</DOC>